Skip to main content
MyPeptideDosagesMyPeptideDosages
single5MG

GHRP-2

5MG Protocol

GHRP-2 5MG

Injection Freq.

Inject once daily

Cycle Sched.

8–16 weeks; some attenuation may occur in first 1–2 weeks but response stabilizes with continued dosing

Reconstitution

3.0 mL BAC water

Robust pulsatile GH release that may support body-composition and metabolic effects
Can significantly increase IGF-1 when paired with GHRH analogs (combination protocols)
Sustained positive effects on growth velocity reported in long-term GH-deficient studies
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–2100 mcg6
2Weeks 3–4150 mcg9
3Weeks 5–8200 mcg12
4Weeks 9–12200 mcg12
5Weeks 13–16200 mcg12

Inject once daily

8–16 weeks; some attenuation may occur in first 1–2 weeks but response stabilizes with continued dosing

GHRP-2 is a synthetic growth hormone secretagogue described as an agonist of the ghrelin (growth hormone secretagogue) receptor. By activating this receptor, it triggers strong, dose-dependent, pulsatile release of growth hormone from the pituitary. The protocol emphasizes that even relatively low doses produced measurable GH increases in clinical research settings, and that repeated administration can sustain responsiveness over extended periods when managed appropriately. In adult physiology, the mechanism is framed as producing discrete GH pulses rather than a continuous GH exposure pattern, aligning with the endocrine system’s normal rhythm. The page also notes that research protocols often balance stimulation with receptor sensitivity, using moderate daily ranges to avoid diminishing returns. Overall, GHRP-2 is positioned as a ghrelin-receptor activator that drives episodic GH release, with downstream relevance to IGF-1 signaling in some combination approaches.
Mild hunger sensation
Transient flushing
Mild injection-site reactions (redness/irritation)
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)

Related peptide protocols

More research-backed dosing guides in this category.